UCB's Global Corporate Website
Welcome to UCB in the United States

Categories

Archives

Sep

01

UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress

Read More Share:linkedin| twitter| email

May

23

UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022

Read More Share:linkedin| twitter| email

May

12

Recognizing the Less Common, but Equally Burdensome, Forms of Arthritis During Arthritis Awareness Month

Read More Share:linkedin| twitter| email

Jan

21

Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

Read More Share:linkedin| twitter| email

Nov

19

Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms

Read More Share:linkedin| twitter| email

© 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
USPR-CORP-0115-00003(2)